Page 21 | Certara

Press Release

Certara Reports First Quarter 2025 Financial Results

RADNOR, PA— May 5, 2025-- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development,…

CertaraMay 5, 2025

On-Demand Webinar

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

Learn how a stepwise C-QTc approach can streamline cardiac safety evaluation, reduce costs, and align…

CertaraMay 5, 2025

Live Events

Annual European Futbol Pharmacometrics Collective

Date: Wednesday, June 4Time: 6:00 PM – 10:00 PMLocation: Football Sport Center — 47 Poseidonos…

CertaraMay 1, 2025

Publication

A translational model-based meta-analysis to predict tremor incidence associated with serotonin reuptake transporter inhibition

The serotonin reuptake transporter (SERT) is responsible for the removal and recycling of the neurotransmitter…

CertaraApril 30, 2025

Poster

Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed/refractory multiple myeloma (RRMM) patient

In partnership with Ichnos, Certara developed a QSP model to determine the most suitable therapeutic…

CertaraApril 30, 2025

Fact Sheet

Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies

Certara’s Non-Animal Navigator™ solution helps companies adapt by selecting and optimizing the best-fit NAM strategies.

CertaraApril 30, 2025

On-Demand Webinar

Combining mechanistic modeling with machine learning to predict clinical scores in inflammatory bowel disease (IBD)

Learn how QSP, virtual patients, and machine learning come together to transform IBD drug development.…

CertaraApril 29, 2025

Press Release

Certara to Participate in Upcoming Investor Conferences

RADNOR, PA — April 29, 2025 -- Certara, Inc. (Nasdaq: CERT), a global leader in…

CertaraApril 29, 2025

Press Coverage

Rare disease drug development: challenges, support and hopes for the future

Explore rare disease drug development challenges, biosimulation solutions, and IRDiRC's significant role in transforming the…

CertaraApril 29, 2025

Conference

Outsourcing in Clinical Trials East Coast 2025

- - Booth

CertaraApril 28, 2025

Certara Reports First Quarter 2025 Financial Results

Explore First: How a Stepwise Approach to QTc Studies Reduces Time, Cost, and Regulatory Risk

Annual European Futbol Pharmacometrics Collective

A translational model-based meta-analysis to predict tremor incidence associated with serotonin reuptake transporter inhibition

Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed/refractory multiple myeloma (RRMM) patient

Non-Animal Navigator™: Expert strategy and AI-enabled biosimulation to reduce, refine, or replace animal studies

Combining mechanistic modeling with machine learning to predict clinical scores in inflammatory bowel disease (IBD)

Certara to Participate in Upcoming Investor Conferences

Rare disease drug development: challenges, support and hopes for the future

Outsourcing in Clinical Trials East Coast 2025

Newsletter sign up

Quick links

Solutions

Contact